Company intelligence / Profile preview

SIRS Therapeutics

Germany

Ownership: Private
Development stage: Other

Overview

SIRS Therapeutics is developing FX06, a fibrin-derived peptide for the treatment of diseases characterized by vascular leakage such as ARDS related to COVID-19. FX06 is being explored in partnership for both pandemic-related and biodefense applications. Early results in animal and human models suggest promise in addressing systemic inflammation and increased capillary permeability, but no published pivotal clinical data as of yet.

Therapeutic areas: Infectious DiseasesPulmonologyCardiovascular
Modalities: PeptidesBiologic
Industry: Biotech

Partnerships

F4 PharmaPartner Therapeutics

Beyond the preview

Go deeper on SIRS Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIRS Therapeutics.

Explore the full profile